Title |
Intervention | NCT ID | Sponsor | Status |
|---|---|---|---|---|
| Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast | Afimoxifene, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration | NCT03063619 | M.D. Anderson Cancer Center | Active, not recruiting |
| Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II... | Exemestane, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery | NCT02598557 | National Cancer Institute (NCI) | Active, not recruiting |
| Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma | Aspirin, Biospecimen Collection, Placebo Administration, Questionnaire Administration, Rectal Biopsy | NCT02965703 | National Cancer Institute (NCI) | Active, not recruiting |
| Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful... | Aspirin, Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration | NCT02521285 | National Cancer Institute (NCI) | Active, not recruiting |
| Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric... | Curcumin, Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment | NCT02782949 | National Cancer Institute (NCI) | Active, not recruiting |
| Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis | Defined Green Tea Catechin Extract, Laboratory Biomarker Analysis, Pharmacological Study, Questionnaire Administration | NCT03278925 | National Cancer Institute (NCI) | Active, not recruiting |
| DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection | Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Rocakinogene Sifuplasmid | NCT02772003 | National Cancer Institute (NCI) | Active, not recruiting |
| Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver | Erlotinib, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment | NCT02273362 | National Cancer Institute (NCI) | Active, not recruiting |
| Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial... | Exemestane, Laboratory Biomarker Analysis, Pharmacokinetic Study, Questionnaire Administration | NCT03300557 | National Cancer Institute (NCI) | Active, not recruiting |
| Iloprost in Preventing Lung Cancer in Former Smokers | Iloprost, Quality-of-Life Assessment, Questionnaire Administration, Placebo Administration | NCT02237183 | National Cancer Institute (NCI) | Active, not recruiting |
Why I Joined a Clinical Trial
At the very first mention of my cancer diagnosis, all I could think of was āHow do I beat thisā¦whatās my best course of action?ā A clinical trial was the answer. I had never heard of Multiple Myeloma, so I wasnāt real confident that there would be a trial for me to join. I was so relieved when there was. How could one not benefit from constant monitoring and undergoing extra testing? I have done extremely well and have had no setbacks. I donāt know if I would be in the same spot if it werenāt for the trial. I am so thankful for the doctors and researchers that work tirelessly toward a cure.